GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Cyclically Adjusted Price-to-FCF

Haisco Pharmaceutical Group Co (SZSE:002653) Cyclically Adjusted Price-to-FCF : (As of Jun. 10, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Haisco Pharmaceutical Group Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Cyclically Adjusted Price-to-FCF Chart

Haisco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 96.60 113.72 269.45 - -

Haisco Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF falls into.



Haisco Pharmaceutical Group Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Haisco Pharmaceutical Group Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Haisco Pharmaceutical Group Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.032/115.2271*115.2271
=-0.032

Current CPI (Mar. 2024) = 115.2271.

Haisco Pharmaceutical Group Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.082 98.200 0.096
201409 0.037 98.900 0.043
201412 0.143 99.000 0.166
201503 -0.040 99.900 -0.046
201506 0.040 99.500 0.046
201509 0.042 100.500 0.048
201512 0.112 100.600 0.128
201603 -0.120 102.200 -0.135
201606 0.197 101.400 0.224
201609 -0.044 102.400 -0.050
201612 0.142 102.600 0.159
201703 -0.112 103.200 -0.125
201706 0.064 103.100 0.072
201709 -0.035 104.100 -0.039
201712 0.085 104.500 0.094
201803 -0.029 105.300 -0.032
201806 0.163 104.900 0.179
201809 0.030 106.600 0.032
201812 -0.055 106.500 -0.060
201903 -0.042 107.700 -0.045
201906 0.089 107.700 0.095
201909 0.014 109.800 0.015
201912 0.099 111.200 0.103
202003 -0.190 112.300 -0.195
202006 -0.183 110.400 -0.191
202009 0.030 111.700 0.031
202012 -0.018 111.500 -0.019
202103 -0.150 112.662 -0.153
202106 -0.177 111.769 -0.182
202109 -0.300 112.215 -0.308
202112 0.007 113.108 0.007
202203 -0.158 114.335 -0.159
202206 -0.111 114.558 -0.112
202209 -0.261 115.339 -0.261
202212 -0.023 115.116 -0.023
202303 -0.044 115.116 -0.044
202306 -0.080 114.558 -0.080
202309 -0.004 115.339 -0.004
202312 0.196 114.781 0.197
202403 -0.032 115.227 -0.032

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Haisco Pharmaceutical Group Co  (SZSE:002653) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Haisco Pharmaceutical Group Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co (SZSE:002653) Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co (SZSE:002653) Headlines

No Headlines